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and Xiaosong Wang1*
Abstract
Background: Our aim is to study the existence of the TLR9/TGF-β1/PDGF-B pathway in healthy humans and
patients with systemic lupus erythematosus (SLE), and to explore its possible involvement in the pathogenesis of
lupus nephritis (LN).
Methods: Protein levels of the cytokines were detected by ELISA. mRNA levels of the cytokines were analyzed by
real-time PCR. MTT assay was used to test the proliferation of mesangial cells under different treatments.
Results: Compared to healthy controls (NControl = 56), levels of Toll-like receptor (TLR)9, transforming growth factor
(TGF)-β1, and platelet-derived growth factor B (PDGF-B) were increased significantly in the peripheral blood of SLE
patients (NSLE = 112). Significant correlations between the levels of TLR9, TGF-β1, and PDGF-B were observed in
both healthy controls and SLE patients. The levels of TGF-β1 and PDGF-B were greatly enhanced by TLR9 activation
in primary cell cultures. The proliferation of mesangial cells induced by the plasma of SLE patients was significantly
higher than that induced by healthy controls; PDGF-B was involved in this process. The protein levels of PDGF-B
homodimer correlated with the levels of urine protein in SLE patients with LN (NLN =38).
Conclusions: The TLR9/TGF-β1/PDGF-B pathway exists in humans and can be excessively activated in SLE patients.
High levels of PDGF-B may result in overproliferation of mesangial cells in the kidney that are involved in the
development of glomerulonephritis and LN. Further studies are necessary to identify TLR9, TGF-β1, and PDGF-B as
new therapeutic targets to prevent the development of glomerulonephritis and LN.
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Background
Toll-like receptor (TLR)9 is expressed by a number of
different immune cell types [1, 2]. It recognizes hypo-
methylated CpG oligonucleotide-motif DNA (CpG) in
bacterial genomes and signals potent inflammatory re-
sponses. Our previously published study has identified
the TLR9/TGF-β1/PDGF-B pathway as a novel signaling
cascade in mouse bone marrow macrophages. It includes
TLR9-mediated signal leading to the induction of
platelet-derived growth factor B (PDGF-B) through the
transforming growth factor (TGF)-β1 auto/paracrine
loop [3].
TLR9 plays crucial roles in the pathogenesis of glomer-
ulonephritis [4–6], though some recent studies report that
TLR9 can be protective in systemic lupus erythematosus
(SLE) patients [7, 8]. TGF-β1 and PDGF-B are important
mediators of extracellular matrix (ECM) accumulation,
fibrosis, and mesangial cell proliferation in glomerulo-
nephritis [9–11]. It is reported that PDGF-B homodi-
mer activates mesangial cells to proliferate and mediate
glomerulosclerosis through matrix production and trans-
differentiation into myofibroblasts [12]. We reported pre-
viously that the TLR9-mediated cascade to the induction
* Correspondence: jlujzy@aliyun.com; gcheng@mednet.ucla.edu;
zhuanhuawang@163.com
†Equal contributors
2Department of Rheumatology and Immunology, the First Hospital, Jilin
University, Changchun 130021, China
1Institute of Translational Medicine, the First Hospital, Jilin University,
Changchun 130061, China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yuan et al. Arthritis Research & Therapy  (2017) 19:70 
DOI 10.1186/s13075-017-1238-8
of PDGF-B is critical to the promotion of mesangial cell
proliferation [3]. All these results suggest a possible mech-
anism of glomerulonephritis in mice: the activation of
TLR9 leads to the secretion of TGF-β1 and PDGF-B,
which induces the production of ECM components as
well as mesangial cell proliferation, migration, and accu-
mulation, and finally leads to glomerulonephritis.
SLE is a systemic autoimmune disease characterized
by the presence of autoantibodies and immune com-
plexes that target multiple organ systems [13]. SLE poses
significant challenges in diagnosis and treatment. In-
depth understanding of the molecular mechanism of the
disease will lead to identifying diagnosis biomarkers and
the development of effective immunotherapy with rele-
vance to the molecules involved in the pathogenesis of
the disease. TLR9 is assumed to be related to the etiology
of SLE in the recognition of anti-DNA antibody contain-
ing immune complexes [14, 15]. The expression of TLR9
in patients with active SLE is found to be significantly
higher than in patients with inactive SLE [16], and it de-
creases significantly after treatment [17]. Lupus nephritis
(LN) is a common manifestation of SLE which is a major
cause of renal insufficiency [18, 19]. It is believed that LN
is induced by autoantibody and immune complex depos-
ition [20]. However, its etiology and pathogenic mecha-
nisms have not been clearly elucidated [21].
It would be revealing to investigate if the TLR9/TGF-
β1/PDGF-B pathway exists in humans as well, which to
our knowledge has not been performed to date. In the
current study, we therefore aimed at exploring the pres-
ence of the TLR9/TGF-β1/PDGF-B pathway in humans,
and comparing the activation of the TLR9/TGF-β1/
PDGF-B pathway between SLE patients and healthy
controls. Furthermore, we explored the possible in-
volvement of the upregulated PDGF-B in SLE patients in
the increased mesangial cell proliferation and the patho-
genesis of glomerulonephritis.
Methods
Patients and sample preparations
Blood samples and clinical indexes from 112 patients
with SLE (see Additional file 1: Table S1) were collected
at the Department of Rheumatology and Immunology,
the first hospital of Jilin University. All patients fulfilled
at least four of the 1997 revised American College of
Rheumatology (ACR) classifications for SLE and did not
present symptoms of active infection or neoplastic disease
at the time of the study. Immunosuppressive treatment
consisted of glucocorticoid plus hydroxychloroquine
(HCQ); some of the patients also received mycophenolate
mofelil (MMF) or azathioprine according to their different
clinical manifestations. Age- and sex-matched blood
samples from 56 healthy people were collected as the
experiment control (see Additional file 1: Table S1); 38
SLE patients with LN were included in this study. LN
was defined by the ACR lupus classification criteria as
proteinuria >0.5 g per day or urinary protein higher
than 3+ by dipstick analysis [22]. The study protocols
and consent forms were approved by the Institutional
Medical Ethics Review Board of the first hospital of Jilin
University, in compliance with the Declaration of Helsinki.
Blood samples were centrifuged at 3000 rpm for 10 min
at room temperature and the obtained plasma was stored
at –20 °C. TRIzol reagent (1 ml; Invitrogen, Carlsbad, CA,
USA) was added to 150 μl whole blood cells and stored
at −80 °C.
Enzyme-linked immunosorbent assay (ELISA)
The concentrations of TGF-β1 (eBioscience) and PDGF-B
(eBioscience) were measured using ELISA kits according
to the manufacturers’ instructions. The ELISA kit used for
protein detection of PDGF-B is specific for PDGF-BB,
which is a homodimer of PDGF-B.
For TGF-β1, samples were prepared before the test pro-
cedure. Plasma or cell culture supernatant samples were
diluted 1:10 with assay buffer (1×) according to the follow-
ing scheme: 20 μl sample + 180 μl assay buffer (1×). HCI
(20 μl 1 N) was added to 200 μl prediluted sample, mixed,
and incubated for 1 h at room temperature. Samples were
neutralized by the addition of NaOH (20 μl 1 N). Human
TGF-β1 standard dilutions ranging from 31 to 2000 pg/ml
were created. The plate was washed twice with approxi-
mately 400 μl wash buffer per well before adding samples,
and then 100 μl of standard dilutions were added to the
standard wells: 100 μl of assay buffer (1×) was added to
the blank wells, and 60 μl of assay buffer (1×) and 40 μl of
pretreated sample were added to the sample wells.
For PDGF-B, samples were prediluted 1:10 with assay
buffer (1×) according to the following scheme: 20 μl
sample + 180 μl assay buffer (1×). The plate was washed
twice with approximately 400 μl wash buffer per well.
Human PDGF-B standard dilutions were created ranging
from 31 to 2000 pg/ml, and 100 μl of standard dilutions
were added to the standard wells: 100 μl of assay buffer
(1×) was added to the blank wells, and 50 μl of assay
buffer (1×) and 50 μl of prediluted samples were added
to the sample wells.
For both TGF-β1 and PDGF-B, each sample, standard,
and blank was assayed in duplicate. After adding the
samples, plate was incubated at room temperature for
2 h on a microplate shaker set at 400 rpm. Next, the
plate was washed and incubated with biotin-conjugate,
streptavidin-HRP and TMB substrate solution in sequen-
tial order following the instructions. When the highest
standard had developed a dark blue color, 100 μl stop so-
lution was added. Absorbance of the plate was read on the
Synergy H1 Hybrid Reader (Biotek, Winooski, VT, USA)
using 450 nm as the primary wavelength. A standard
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curve was generated from the readings of the diluted
standards. Sample concentrations were calculated based
on their absorbance compared to the standard curve. All
of the samples were tested twice and the results were
averaged.
Real-time quantitative polymerase chain reaction (qPCR)
Total RNA was extracted from whole blood cells or
isolated monocytes using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). The purity of RNA was determined
by absorbance at 260 nm and 280 nm on the Synergy H1
Hybrid Reader (Biotek, Winooski, VT, USA). The integrity
of RNA was monitored by analyzing the intensity of ribo-
somal 18S and 28S RNA with an Agilent 2100 bioanalyser
(Agilent Techonlogies, Santa Clara, CA, USA). Extracted
RNA (1 μg) was reverse-transcribed using the PrimeScript
RT Reagent Kit (TAKARA, Kyoto, Japan). Diluted cDNA
(1:20; 5 μl) was amplified using the Fast Start Univer-
sal SYBR Green Master (Roche Diagnostics GmbH,
Mannheim, Germany) and quantitative PCR using specific
primers (synthesized by Sangon Biotech, Shanghai, China).
The qPCR assays were carried out in duplicate on the
Applied Biosystems Step one plus instrument (Step one
software 2.2). The cycling conditions were 10 min poly-
merase activation at 95 °C, followed by 40 cycles at 95 °C
for 10 s and 60 °C for 30 s. The threshold was set above
the nontemplate control background and within the linear
phase of the target gene amplification to calculate the
cycle number at which the transcript was detected (Ct)
[23]. In all of our experiments, each sample was tested
twice; every Ct value was the average of the results from
two wells. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was selected as the reference gene. The method
of 2–ΔΔCT was used to analyze the real-time PCR data
expressed as the fold-change relative to the average value
of the GAPDH [24, 25].
Cell culture and treatment
Whole blood samples were diluted at 1:10 in the RPMI
1640 medium with 100 units/ml penicillin and 100 μg/
ml streptomycin at 37 °C in 5% CO2 atmosphere for
24 h [26, 27]. Class B CpG (ODN 2006 sequence 5′-
tcgtcgttttgtcgttttgtcgtt-3′) was used as the TLR9 agonist.
For Fig. 4, cells from SLE patients or healthy controls
were incubated with or without CpG (Sangon Biotech)
at a final concentration of 500 nM for 24 h, and then
cells were harvested, lysed with TRIzol reagent, and
stored at –80 °C for RNA extractions. Results are shown
as the average of the triplicated wells for each sample
and each treatment. For Fig. 5, cells from SLE patients
were incubated with or without recombinant human
TGF-β1 (final concentration 2.5 ng/ml; R&D Systems,
Minneapolis, MN, USA), SB431542 (final concentration
5 μM; Sigma-Aldrich, St. Louis, MO, USA), anti-human
TGF-β1 antibody 1D11 (final concentration 1 μg/ml;
R&D Systems), and CpG (final concentration 500 nM;
Sangon Biotech) for 24 h. Then cells were harvested,
lysed with TRIzol reagent, and stored at –80 °C for RNA
extractions. Supernatants were collected and stored at –
20 °C. Results are shown as the average of triplicated
wells for each sample and each treatment. For Fig. 6,
anti-human PDGF-B (homodimer) polyclonal antibody
(R&D Systems) and isotype control antibody (R&D Sys-
tems) were added into the culture at a final concentra-
tion of 1 or 10 μg/ml; detailed information can be found
in the next paragraph. For Additional file 2: Figure S1,
peripheral blood mononuclear cells (PBMCs) were iso-
lated from the peripheral blood of SLE patients by lym-
phoprep density-gradient centrifugation (Axis-Shield PoC
AS, Oslo, Norway). Monocytes were isolated using human
CD14 magnetic beads (Miltenyi Biotec; the purity was
generally >95%) from PBMC for cell culture. Monocytes
were incubated with or without CPG at a final concentra-
tion of 500 nM for 24 h, and then cells were harvested,
lysed with TRIzol reagent, and stored at –80 °C for RNA
extractions. Results are shown as the average of the tripli-
cated wells for each sample and each treatment.
Cell proliferation assay
Mycoplasma-free SV40 MES 13 (Murine Mesangial)
cells were from the American Type Culture Collection
(Manassas, VA, USA) at passage 27. Cells were maintained
in Dulbecco’s modified Eagle’s medium/F12 medium (3:1)
supplemented with both 14 mM HEPES (pH 7.4) and 5%
fetal bovine serum (FBS). Cell monolayers were routinely
grown to confluence in a humidified 37 °C, 5% CO2 in-
cubator before testing. All experiments were performed
between passages 30 and 40 to minimize the effects of
phenotypic variation in continuous culture. Cell prolifera-
tion was measured using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT; Sigma-
Aldrich) assay: 103 cells/200 μl/well were seeded in a
96-well microplate and were serum starved in RPMI1640
without FBS for 24 h before treatments. For Fig. 6a, 200 μl
culture medium of whole blood cells from SLE patients
stimulated with CpG (500 nM) was added into starved
mesangial cells and cultured for 4 h. For Fig. 6b, after su-
pernatants were removed from starved mesangial cells,
190 μl RPMI 1640 (without FBS) and 10 μl plasma from
SLE patients or healthy controls was added and cultured
for 20 h. For Fig. 6c, after supernatants were removed
from starved mesangial cells, 190 μl RPMI 1640 (without
FBS; with or without antibodies) and 10 μl plasma from
SLE patients was added and cultured for 20 h. The final
concentration of anti-PDGF-B (homodimer) neutralizing
antibody and control antibody were 1 or 10 μg/ml. Then,
20 μl MTT solution (5 mg/ml) was added and the incuba-
tion continued for another 4 h. Finally, the medium was
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carefully changed with 150 μl dimethylsulfoxide (DMSO)
and the optical density was measured at 570 nm with a
microplate reader. Each culture condition for each patient
or control was repeated in six wells in parallel; the result
is the average reading of these six wells.
Statistical analysis
Statistical analyses were performed using Graphpad Prism
5.0 (GraphPad Software, San Diego CA, USA). Wilcoxon
signed rank test for paired samples and Mann-Whitney U
test for unpaired samples were applied. The nonpara-
metric Spearman rank correlation test was applied for
the correlation studies. p < 0.05 was considered statisti-
cally significant.
Results
Increased levels of TLR9, TGF-β1, and PDGF-B in peripheral
blood of SLE patients
First, by measuring the levels of TLR9, TGF-β1, and
PDGF-B in the peripheral blood of SLE patients, we
studied the possible involvement of the TLR9/TGF-β1/
PDGF-B pathway in the pathogenesis of SLE. The
mRNA levels of TLR9 in the blood cells of SLE patients
were significantly higher than those of healthy controls
(p = 0.0048; Fig. 1a). Furthermore, SLE patients showed
much higher protein levels of TGF-β1 (p < 0.0001; Fig. 1b)
and PDGF-B (p = 0.0084; Fig. 1c) compared to healthy
controls. The SLE Disease Activity Index (SLEDAI) is an
indicator of the disease activity of SLE. Two weeks after
immunosuppressive treatment, the SLEDAI of patients
decreased significantly (p < 0.0001; Fig. 1d), which indi-
cates that SLE is being effectively alleviated. TGF-β1 and
PDGF-B levels in the same group of patients at these two
time points were compared as well. With the decrease in
disease activity, levels of TGF-β1 (p < 0.0001; Fig. 1e) and
PDGF-B (p = 0.0255; Fig. 1f) in SLE patients decreased
greatly. These results suggest that TLR9, TGF-β1, and
PDGF-B may be involved in the pathogenesis of SLE.
Correlations among levels of TLR9, TGF-β1, and PDGF-B in
peripheral blood
We previously reported that the TLR9 agonist regulates
PDGF-B production and cell proliferation through a
TGF-β1 signal in mice [3]. To establish the relevance of
these findings in humans, the relationship between levels
of TLR9, TGF-β1, and PDGF-B in peripheral blood were
studied. Results showed that protein levels of PDGF-B
closely correlated with TGF-β1 in healthy controls (p <
0.0001, r = 0.61; Fig. 2a). Protein levels of PDGF-B corre-
lated with TGF-β1 in SLE patients (p < 0.0001, r = 0.68;
Fig. 2e) as well. Accordingly, the mRNA levels of
TGF-β1 correlated closely with PDGF-B both in healthy
controls (p = 0.0268, r = 0.33; Fig. 2b) and in SLE patients
(p < 0.0001, r = 0.61; Fig. 2f). Furthermore, a significant
correlation between mRNA levels of TLR9 and TGF-β1
(p = 0.0003, r = 0.51; Fig. 2c) and great correlation between
mRNA levels of TLR9 and PDGF-B (p = 0.0018, r = 0.45;
Fig. 2d) were detected in healthy controls. Moreover, it
Fig. 1 Levels of Toll-like receptor 9 (TLR9), transforming growth factor-β1 (TGF-β1), and platelet-derived growth factor-B (PDGF-B) in the peripheral
blood of systemic lupus erythematosus (SLE) patients. The mRNA expression of TLR9 (a) in the peripheral blood of SLE patients (NSLE = 112) and
healthy controls (NControl = 49). Levels of TGF-β1 (b) and PDGF-B (c) in the plasma of SLE patients (NSLE = 77) and healthy controls (NControl = 56).
Levels of SLE Disease Activity Index (SLEDAI) (d), TGF-β1 (e), and PDGF-B (f) in the same group of SLE patients (NSLE = 20) before and after
immunosuppressive treatment. The results in a.b.c. are presented as Mean and SEM. GAPDH glyceraldehyde-3-phosphate dehydrogenase
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was found that mRNA levels of TLR9 were correlated
with TGF-β1 (p < 0.0001, r = 0.52; Fig. 2g) and PDGF-B
(p < 0.0001, r = 0.45; Fig. 2h) in SLE patients. Overall,
significant correlations between the levels of TLR9,
TGF-β1, and PDGF-B were observed in the blood of
both SLE patients and healthy controls. These results
support the hypothesis that the signal pathway of
TLR9/TGF-β1/PDGF-B exists both in healthy controls
and in SLE patients.
Correlations between levels of TLR9 and MCP-1, TLR9 and
ISG15, or TLR9 and IFNα
In order to make comparisons with TLR9, TGF-β1,
and PDGF-B, other cytokines (including monocyte
chemoattractant protein (MCP)-1, interferon-stimulated
gene (ISG)15, and interferon (IFN)α) were detected in
SLE patients. The levels of MCP-1 (p = 0.0039; Fig. 3a),
ISG15 (p = 0.0004; Fig. 3b), and IFNα (p = 0.0073; Fig. 3c)
were found to increase significantly in the peripheral
blood of SLE patients compared to that of healthy con-
trols. Next, the correlations between the levels of TLR9
and theses cytokines were analyzed. It was found that, un-
like TGF-β1 and PDGF-B, no significant correlation was
found between TLR9 and MCP-1 (p = 0.2544, r = 0.1091;
Fig. 3d), TLR9 and ISG15 (p = 0.9722, r = –0.0072; Fig. 3e),
or TLR9 and IFNα (p = 0.1247, r = –0.3549; Fig. 3f).
The mRNA expressions of TGF-β1 and PDGF-B enhanced
by TLR9 activation
We further explored the possible existence of the TLR9/
TGF-β1/PDGF-B pathway in healthy humans and SLE
patients in primary cell cultures. As the assay mimics
the natural environment, whole blood stimulation has
been used to investigate the cellular responsiveness to a
variety of stimuli [28]. CpG was added to the culture as
a specific stimulus for TLR9. As shown in Fig. 4, CpG
can significantly upregulate the mRNA levels of TGF-β1
(p = 0.0210; Fig. 4a) and PDGF-B (p = 0.0093; Fig. 4b) in
the blood cells of healthy controls and SLE patients
(TGF-β1: p = 0.0005; Fig. 4c) (PDGF-B: p = 0.0005;
Fig. 4d). These results support the hypothesis that the
TLR9/TGF-β1/PDGF-B pathway exists in both healthy
controls and SLE patients. Next, to investigate the extent
of the activation of this pathway in these two groups,
multiples of TGF-β1 and PDGF-B increased by CpG-
stimulation in healthy humans and SLE patients were
compared. It was found that CpG can induce much
higher levels of TGF-β1 (p = 0.0485; Fig. 4e) and PDGF-
B (p = 0.0037; Fig. 4f ) in the cells from SLE patients than
those from healthy controls. Similar results were also
found in isolated monocytes from SLE patients and
healthy controls (see Additional file 2: Figure S1). It is
speculated that the TLR9/TGF-β1/PDGF-B pathway may
be overactivated in SLE patients, and the overactivation is
related to the increased levels of TLR9, TGF-β1, and
PDGF-B shown in Fig. 1.
PDGF-B production induced by TGF-β1
To verify the role of TGF-β1 in the production of
PDGF-B in SLE patients, human recombinant protein
TGF-β1 was added to the culture. It was found that
TGF-β1 increased protein levels (p = 0.0156; Fig. 5a)
and mRNA levels (p = 0.0020; Fig. 5c) of PDGF-B sig-
nificantly. On the other hand, the TGF-β1 antagonists
Fig. 2 Correlations among levels of Toll-like receptor 9 (TLR9), transforming growth factor-β1 (TGF-β1), and platelet-derived growth factor-B
(PDGF-B) in human peripheral blood. Correlations between protein levels of TGF-β1 and PDGF-B in healthy controls (a; NControl = 56) and systemic
lupus erythematosus (SLE) patients (b; NSLE = 79). Correlations between mRNA expression of TGF-β1 and PDGF-B in healthy controls (c; NControl = 46)
and SLE patients (d; NSLE = 106). Correlations between TLR9 and TGF-β1 (e,f), or between TLR9 and PDGF-B (g,h). The mRNA expression of healthy
controls (e,g; NControl = 46) and that of SLE patients (f,h; NSLE = 106). GAPDH glyceraldehyde-3-phosphate dehydrogenase
Yuan et al. Arthritis Research & Therapy  (2017) 19:70 Page 5 of 12
Fig. 4 CpG induces upregulation of transforming growth factor-β1 (TGF-β1) and platelet-derived growth factor-B (PDGF-B) in vitro. Blood cells
from healthy controls (a,b; NControl = 12) and systemic lupus erythematosus (SLE) patients (c,d; NSLE = 16) were stimulated with or without 500 nM
CpG for 24 h, and then the mRNA expression of TGF-β1 and PDGF-B were detected by qPCR. Multiple rates of mRNA expression of TGF-β1 (e)
and PDGF-B (f) in healthy controls (NControl = 12) and SLE patients (NSLE = 16) were calculated as CpG/Media. The results were presented as mean
and SEM. GAPDH glyceraldehyde-3-phosphate dehydrogenase
Fig. 3 Levels of monocyte chemoattractant protein-1 (MCP-1), interferon-stimulated gene 15 (ISG15), and interferon alpha (IFN-α) and their correlations
with Toll-like receptor 9 (TLR9) in systemic lupus erythematosus (SLE) patients. The mRNA expression of MCP-1 (a; NControl = 49, NSLE = 111),
ISG15 (b; NControl = 26, NSLE = 34), and IFNα (c; NControl = 12, NSLE = 26) in the peripheral blood of SLE patients and healthy controls. The results
in a.b.c are presented as Mean and SEM. Correlations between levels of TLR9 and MCP-1 (d; NSLE = 111), ISG15 (e; NSLE = 26), or IFNα (f; NSLE = 20).
GAPDH glyceraldehyde-3-phosphate dehydrogenase
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TGF-β1 RI/ALK inhibitor SB431542 and neutralizing
anti-TGF-β1 monoclonal antibody 1D11 inhibited the
production of PDGF-B significantly at both the protein
level (p < 0.05; Fig. 5b) and mRNA level (p < 0.05;
Fig. 5d). These results suggest that TGF-β1 induces
PDGF-B production in the primary peripheral blood
cells of SLE patients in vitro. Moreover, SB431542 sig-
nificantly inhibited the PDGF-B production induced by
CpG (p < 0.05; Fig. 5e), indicating that TGF-β1 is greatly
involved in the process of CpG-induced PDGF-B produc-
tion in SLE patients. Therefore, CpG upregulates the pro-
duction of PDGF-B through its induction of TGF-β1. All
these results confirmed that the TLR9/TGF-β1/PDGF-B
pathway exists in the peripheral blood of SLE patients.
Higher proliferation rate of mesangial cells in SLE patients
involves PDGF-B
PDGF-B has been recognized as a cytokine to mediate
glomerulonephritis through induction of mesangial cell
proliferation [10]. To determine if CpG-specific induc-
tion of PDGF-B in SLE patients affects mesangial cell
proliferation, we analyzed mesangial cell proliferation by
MTT assay following stimulation with culture medium
from blood cells stimulated by CpG. Results showed that
the supernatant of CpG-stimulated primary cells from
SLE patients can potently induce mesangial cell prolifer-
ation (p = 0.0171; Fig. 6a). By adding plasma to the cul-
ture medium of mesangial cells and measuring the cell
proliferation, it was found that plasma from SLE patients
induced a much higher proliferation rate than that from
healthy controls (p = 0.0116; Fig. 6b). Anti-PDGF-B neu-
tralizing antibody inhibited mesangial cell proliferation
induced by the plasma of patients in a dose-dependent
manner (p < 0.05; Fig. 6c). These results indicate that the
high levels of PDGF-B in the peripheral blood of SLE
patients may have effectively induced mesangial cell
proliferation and glomerulonephritis in these patients.
PDGF-B levels of SLE patients with LN
Glomerulonephritis of SLE patients is involved in the
pathogenesis of LN. By analyzing the levels of TLR9,
TGF-β1, and PDGF-B in SLE patients with LN, significant
correlations were found between the mRNA expressions
of TGF-β1 and PDGF-B (p = 0.0092, r = 0.61; Fig. 7a), the
mRNA expressions of TLR9 and TGF-β1 (p = 0.0003,
r = 0.51; Fig. 7b), and the mRNA expressions of TLR9 and
PDGF-B (p = 0.0052, r = 0.44; Fig. 7c). Positive correlations
were also found between the protein levels of TGF-β1 and
Fig. 5 Transforming growth factor-β1 (TGF-β1) induces the production of platelet-derived growth factor-B (PDGF-B) in vitro. Protein levels of
PDGF-B in blood cell cultures of SLE patients with or without 2.5 ng/ml recombinant protein TGF-β1 (a; NSLE = 7), and with or without TGF-β1
antagonists (5 μM SB431542, 1 μg/ml αTGF-β1) (b; NSLE = 6). The mRNA expression of PDGF-B in blood cell cultures of SLE patients with or
without 2.5 ng/ml recombinant protein TGF-β1 (c; NSLE = 10), and with or without TGF-β1 antagonists (5 μM SB431542, 1 μg/ml αTGF-β1) (d; NSLE = 9).
The mRNA expression of PDGF-B in blood cultures of SLE patients with 500 nM CpG, 5 μM SB431542, or 500 nM CpG plus 5 μM SB431542
(e; NSLE = 16). Cells were cultured for 24 h, and then mRNA expressions were detected by qPCR. The results are presented as mean and SEM.
GAPDH glyceraldehyde-3-phosphate dehydrogenase
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PDGF-B (p < 0.0001, r = 0.64; Fig. 7d) in these patients.
Kidney damage leads to proteinuria in SLE patients with
LN. In order to further explore the possible involvement of
the TLR9/TGF-β1/PDGF-B pathway in the pathogenesis of
LN, the protein levels of PDGF-B homodimer were
compared with the urine protein levels in SLE patients
with LN. Results showed that the protein levels of PDGF-B
homodimer correlated with the levels of urine protein
(p = 0.0027, r = 0.49; Fig. 7e) in SLE patients with LN.
In this study, we investigated the existence of the sig-
naling transduction pathway of TLR9/TGF-β1/PDGF-B
in humans and the excessive activation of this pathway
in SLE patients. Moreover, the possible involvement of
the TLR9/TGF-β1/PDGF-B pathway in the pathogenesis
of SLE was explored.
Discussion
Our current study observed the presence of the TLR9/
TGF-β1/PDGF-B pathway both in healthy humans and
in SLE patients. Our data suggest the activation of this
pathway increases in SLE patients, which may play an
Fig. 6 Mesangial cell proliferation induced by platelet-derived growth factor-B (PDGF-B) from blood cells of systemic lupus erythematosus (SLE)
patients. Mesangial cells were serum starved for 24 h and then stimulated for 4 h with culture medium from blood cells of SLE patients (a; NSLE = 8)
stimulated with 500 nM CpG. Mesangial cells were serum starved for 24 h and then stimulated for 20 h with plasma from SLE patients (b; NSLE = 13) or
healthy controls (b; NControl = 13) in culture medium. Mesangial cells were serum starved for 24 h and then stimulated for 20 h with plasma from SLE
patients (c; NSLE = 6), with anti-PDGF-B neutralizing antibody (1 or 10 μg/ml) or control antibody (1 or 10 μg/ml) added. Proliferation was measured by
MTT assay. The results are presented as mean and SEM
Fig. 7 Levels of Toll-like receptor 9 (TLR9), transforming growth factor-β1 (TGF-β1), and platelet-derived growth factor-B (PDGF-B) and proteinuria
in SLE patients with LN. Correlations between mRNA expression of TGF-β1 and PDGF-B (a; NLN = 38). Correlations between mRNA expression of
TLR9 and TGF-β1 (b; NLN = 38). Correlations between mRNA expression of TLR9 and PDGF-B (c; NLN = 38). Correlations between protein levels of
TGF-β1 and PDGF-B (d; NLN = 38). Correlations between protein levels of TGF-β1 and PDGF-B (d; NLN = 38). Correlations between protein levels of
PDGF-B and urine protein (e; NLN = 38). GAPDH glyceraldehyde-3-phosphate dehydrogenase
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important role in promoting mesangial cell proliferation
and contribute to glomerulonephritis of LN.
This is the first time that human samples have been
used to study the presence of the TLR9/TGF-β1/PDGF-B
pathway in SLE patients and healthy controls. Significant
correlations between TLR9, TGF-β1, and PDGF-B were
found both at the protein level and mRNA level in SLE
patients and healthy controls, while no significant
correlation was found between TLR9 and MCP-1, TLR9
and ISG15, or TLR9 and IFNα. Therefore, the TLR9/
TGF-β1/PDGF-B pathway may be present both in SLE
patients and healthy controls. Next, the possible existence
of this pathway in humans observed in vivo was confirmed
by cell culture experiments in vitro. CpG can significantly
increase the production of TGF-β1 and PDGF-B in blood
cells from both healthy controls and SLE patients. 1D11 is
a neutralizing antibody of human TGF-β1. SB431542
selectively inhibits the phosphorylation of Smad3, and
thereby inhibits TGF-β1-induced orientation of Smad3 in
the nucleus [29]. TGF-β1 antagonists 1D11 and SB431542
significantly inhibited the production of PDGF-B, sug-
gesting that TGF-β1 is involved in the process of
TLR9-induced PDGF-B production in humans.
To further explore the activation levels of the pathway
in these two groups of people, we compared the CpG ef-
fects on the production of PDGF-B in healthy controls
and SLE patients; it was found that blood cells of SLE
patients did produce much higher levels of TGF-β1 and
PDGF-B than those of healthy controls. The TLR9/TGF-
β1/PDGF-B pathway can be excessively activated in SLE
patients compared to healthy controls. This could be
one of the explanations for the increased levels of TLR9,
TGF-β1, and PDGF-B in the peripheral blood of SLE pa-
tients compared to healthy controls. We put forward the
hypothesis that higher activation levels of the TLR9/
TGF-β1/PDGF-B pathway in SLE patients are associated
with increased levels of TLR9, TGF-β1, and PDGF-B in
the blood of SLE patients. It is worth mentioning that
higher levels of protein expression of TLR9 have been
reported in monocytes and different lymphocyte subsets
from SLE patients compared with healthy controls by
flow cytometry [30]. In addition, a significant reduction
in SLEDAI after immunosuppressive treatment is associ-
ated with the decreases in TGF-β1 and PDGF-B. In agree-
ment with these findings, increased TGF-β1 production
and increased urinary levels of TGF-β1 were reported in
SLE patients [31, 32]. On the other hand, increased levels
of TGF-β1 found in SLE patients contradicts a study that
showed lower levels of TGF-β1 in these patients [33]. Xing
et al. found that TGF-β1 levels were higher in the urine of
LN patients, though they were decreased in the serum of
SLE patients [34]. It is not clear whether these differences
in results may be due to the racial difference between the
patients groups involved in the research.
Increased levels of TLR9, TGF-β1, and PDGF-B in SLE
patients indicate the upregulation of this pathway. We
further explored the possible involvement of this pathway
in the pathogenesis of glomerulonephritis. We found that
culture media of CpG-stimulated blood cells were able to
stimulate mesangial cell proliferation greatly, which was
an important character of glomerulonephritis. Compared
to healthy controls, plasma from SLE patients can sig-
nificantly increase the proliferation of mesangial cells
as well. Moreover, this proliferation can be inhibited by
neutralizing anti-PDGF-B antibodies. These results sug-
gest that, at least partly because of the increased levels
of PDGF-B coming from elevated TLR9/TGF-β1/PDGF-B
pathway activation, plasma of SLE patients can promote
mesangial cell proliferation significantly. Endogenous
DNA-containing autoantibody complexes stimulate TLR9
and induce inflammation in SLE patients [35]. Therefore,
in SLE patients, DNA fragments may overactivate the
TLR9/TGF-β1/PDGF-B pathway to produce large
amounts of TGF-β1 and PDGF-B. TGF-β1 can induce fi-
brosis in the kidney, while PDGF-B further stimulates the
proliferation of mesangial cells. Just like in control and
SLE patients, significant correlations have been ob-
served between TLR9, TGF-β1, and PDGF-B in SLE pa-
tients with LN. Proteinuria is an important character of
glomerulonephritis and LN. Furthermore, the levels of
urine protein have been found to correlate with the levels
of PDGF-B greatly in SLE patients with LN. Similarly,
PDGF-B expression has been shown to strongly correlate
with the severity of IgA glomerulonephritis, especially in
terms of proliferative glomerular changes [36]. These re-
sults support the hypothesis that the TLR9/TGF-β1/
PDGF-B pathway is involved in the mechanisms causing
LN in SLE patients. In agreement with this, it is reported
that mRNA levels of TLR9 are significantly higher in SLE
patients with LN than in those without LN [37]. Our pub-
lished results have proved that the TLR9 agonist induces
PDGF-B production and cell proliferation through TGF-
β1 signaling in mouse bone marrow macrophages [3]. It
has also been reported that CpG accelerates the develop-
ment of LN during the pre-active phase in NZB ×NZWF1
mice [38].
TGF-β is an attractive therapeutic target, especially in
chronic inflammation and tumors [39, 40]. Recombinant
human anti-TGF-β1 antibody has been used in the ther-
apy of systemic sclerosis in clinical trials [41]. Our current
study demonstrates the effectiveness of neutralizing
anti-PDGF-B antibodies in preventing mesangial cell
proliferation in vitro. CpG-DNA/TLR9-mediated glom-
erulonephritis as well as the transition from inflammation
to fibrosis may be inhibited by targeted inhibition of TGF-
β1 and PDGF-B through antibody therapy. Cytotoxic
agents and corticosteroids are standard treatments for LN
with considerable morbidity and suboptimal outcomes
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[42]. With further clarification of the overactivated path-
way of TLR9/TGF-β1/PDGF-B in LN patients, it is critical
to study TLR9, TGF-β1, or PDGF-B antagonists in the pre-
vention and treatment of LN.
There are several limitations to our study. First, we did
not perform immunohistochemical staining to localize
the expression of TLR9, TGF-β1, or PDGF-B in the kid-
neys of SLE patients. However, similar studies have been
reported separately. Machida et al. found that TLR9 is
not expressed in normal kidneys, but TLR9 develops in
podocytes in active LN patients and disappears in remis-
sion [14]. Immunofluorescence staining of kidney biop-
sies showed substantial expression of TGF-β1 in LN
patients [43]. The mRNA of PDGF-B and PDGF-β re-
ceptor was observed in the kidney of LN patients but
not in healthy controls by in situ hybridization [44]. We
are therefore confident that increased TLR9, TGF-β1,
and PDGF-B can be observed in the kidney of SLE pa-
tients compared to healthy controls, and that part of this
increase may be recruited from the blood. Second, the
cell types that respond to CpG for the production of
TGF-β1 and PDGF-B were not specified. From previous
studies, TLR9 was found to be expressed mainly in plas-
macytoid dendritic cells of healthy humans [45–47]. In-
creased levels of TLR9 have been found in different cell
types (T cells, B cells, monocytes) in the blood of SLE pa-
tients compared to healthy controls [30, 48], but the exact
blood cell types that express TLR9 in SLE patients have
not been clearly identified. As a multiple functional cyto-
kine, TGF-β1 can be produced by both innate and adap-
tive immune cells such as monocytes/macrophages,
dendritic cells, and T lymphocytes. A specific cell-type
culture has the significant limitation of missing the oppor-
tunity to observe the results of the cell-cell interaction
under natural conditions. Therefore, whole blood assays
were utilized here to yield results that may be more repre-
sentative of the complex condition in vivo. On the other
hand, similar results have been observed in the culture ex-
periments utilizing monocytes isolated from the blood
of SLE patients compared to that utilizing whole blood
cells (see Additional file 2: Figure S1). Our studies focus
on proving that the TLR9/TGF-β1/PDGF-B pathway
found in mice also exists in humans; we provide new evi-
dence that TLR9 signals to induce TGF-β1 and PDGF-B,
which are critical mediators of glomerulonephritis. Finally,
this study supports the presence and overactivation of the
TLR9/TGF-β1/PDGF-B pathway in SLE patients, but its
link to the pathogenesis of LN requires further supporting
evidence. We cannot make the conclusion that TLR9,
TGF-β1, or PDGF-B antagonists can be used as treat-
ments for LN, though we hypothesize that TLR9, TGF-β1,
and PDGF-B may serve as new therapeutic targets for
SLE. In agreement with this hypothesis, Fukasawa et al.
have successfully treated chronic progressive nephritis of
rats with anti-TGF-β antibody by inhibiting Smad/TGF-β
signaling [49]. Moreover, the tyrosine kinase inhibitor of
the PDGF receptor, imatinib, has been reported to
ameliorate LN in mouse models including NZB/W
lupus mice and MRL/lpr mice [50, 51].
Conclusions
Our results show the TLR9/TGF-β1/PDGF-B pathway
exists in humans and that it is overactivated in the per-
ipheral blood of SLE patients. Further analysis on the
involvement of this pathway in the pathogenesis of
glomerulonephritis may provide important additional
information to assist the physician in understanding the
underlying cause of LN, which may lead to development
of TLR9, TGF-β1, or PDGF-B antagonists to prevent the
development of renal fibrosis and renal failure in LN.
Additional files
Additional file 1: Table S1. Clinical data of the study subjects. (XLS 23 kb)
Additional file 2: Figure S1. CpG induces upregulation of TGF-β1 and
PDGF-B in monocytes in vitro. Isolated monocytes from healthy controls
(A and B; NControl = 8) and SLE patients (C and D; NSLE = 7) were stimulated
with or without 500 nM CpG for 24 h, and then mRNA expression of TGF-β1
and PDGF-B were detected by qPCR. Multiple rates of mRNA expression of
TGF-β1 (E) and PDGF-B (F) in healthy controls (NControl = 8) and SLE patients
(NSLE = 7) were calculated as CpG/Media. The results are presented as mean
and SEM. (PPTX 510 kb)
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